Seattle Genetics is a leading biotechnology company, paving the way for innovative cancer therapies. They are an industry leader in anti-body drug conjugates (ADCs), which is a technology that manipulates the targeting ability of monoclonal anti-bodies. These ADCs will deliver cell killing agents directly to cancer cells. This cutting edge therapy is intended to lessen the debilitating effects of chemotherapy. In addition to this major product, they are researching other products to met the needs of cancer therapies.
They are advancing new and innovative therapies with less harmful effects on patients. They value research, scientific excellence, and teamwork. These values are reflected through their new and breakthrough products. They are currently in trials for several new therapies, such as lymphoma, leukemia, and solid tumors. Seattle Genetics shows their excellence through the success of the therapies and improving the lives of patients.
Dr. Clay Siegall, who co-founded Seattle Genetics in 1998, is currently the President, CEO, and Chairman of the board. He brought his experience from industry giants, like National Institute of Health and National Cancer Institute. He has helped the company earn 1.2 billion in 2001, and the company made IPO that year. Clay Siegall has helped through a partnership with Takeda Pharmaceuticals to secure a patent for its first ADC product, Adcetris. He continues to push the company to the next level of scientific innovation.
Learn more about Doctor Siegall